Wave Life Sciences, Inc. (WVE)
3.18
-0.17
(-5.07%)
USD |
NASDAQ |
Oct 23, 16:00
3.175
0.00 (0.00%)
After-Hours: 20:00
Wave Life Sciences Enterprise Value : 167.61M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 167.61M |
| October 22, 2026 | 200.47M |
| October 21, 2026 | 204.33M |
| October 20, 2026 | 214.00M |
| October 19, 2026 | 165.68M |
| October 16, 2026 | 157.95M |
| October 15, 2026 | 169.54M |
| October 14, 2026 | 150.22M |
| October 13, 2026 | 159.88M |
| October 12, 2026 | 186.94M |
| October 09, 2026 | 221.73M |
| October 08, 2026 | 223.66M |
| October 07, 2026 | 237.19M |
| October 06, 2026 | 233.33M |
| October 05, 2026 | 277.78M |
| October 02, 2026 | 283.58M |
| October 01, 2026 | 302.91M |
| September 30, 2026 | 268.12M |
| September 29, 2026 | 256.52M |
| September 28, 2026 | 262.32M |
| September 25, 2026 | 283.58M |
| September 24, 2026 | 318.37M |
| September 23, 2026 | 316.43M |
| September 22, 2026 | 393.75M |
| September 21, 2026 | 375.38M |
| Date | Value |
|---|---|
| September 18, 2026 | 393.75M |
| September 17, 2026 | 411.14M |
| September 16, 2026 | 423.70M |
| September 15, 2026 | 415.01M |
| September 14, 2026 | 438.20M |
| September 11, 2026 | 440.13M |
| September 10, 2026 | 455.59M |
| September 09, 2026 | 482.65M |
| September 08, 2026 | 501.98M |
| September 04, 2026 | 492.32M |
| September 03, 2026 | 461.39M |
| September 02, 2026 | 496.18M |
| September 01, 2026 | 513.58M |
| August 31, 2026 | 500.05M |
| August 28, 2026 | 527.11M |
| August 27, 2026 | 550.30M |
| August 26, 2026 | 563.83M |
| August 25, 2026 | 567.70M |
| August 24, 2026 | 542.57M |
| August 21, 2026 | 575.43M |
| August 20, 2026 | 567.70M |
| August 19, 2026 | 599.59M |
| August 18, 2026 | 575.43M |
| August 17, 2026 | 536.77M |
| August 14, 2026 | 598.62M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -51.98M |
| CorMedix, Inc. | 497.49M |
| Eloxx Pharmaceuticals, Inc. | -10.30M |
| Breakthrough Chemistry, Inc. | 0.2897M |
| BioStem Technologies, Inc. | 22.24M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -69.36M |
| Revenue (Quarterly) | 2.272M |
| Total Expenses (Quarterly) | 71.63M |
| EPS Diluted (Quarterly) | -0.34 |
| Gross Profit Margin (Quarterly) | -4.27% |
| Profit Margin (Quarterly) | -3.05K% |
| Earnings Yield | -34.17% |
| Normalized Earnings Yield | -34.17 |